Biomedtracker

Report Library

Post-AASLD EU KOL Interview

December 16, 2014

Following our live coverage of AASLD, we interviewed an EU KOL to expand on how the data events and discussions at the meeting will impact the current treatment practices in Hepatitis C. Additionally, we discussed drugs in development for NASH and Hepatitis B and any relevant data from the meeting in these indications.

Key Highlights

Price will play a large roll in the usage of newly approved drugs in the EU. Access will vary widely from country to country (GILD, ABBV, BMY).
Rollout of Harvoni has been happening slowly and its use is restricted primarily to patients with >F2 (GILD).
The hope is that the ABBY 3D will be about 30,000 USD in the EU (ABBV). EU physicians will use either ABBV 3D or BMY Trio and use Harvoni as needed for retreatment if the cost-savings is sufficient (GILD).
Daclatasvir in combination with sofosbuvir will be preferred in GT3 patients still. The EU has better access via compassionate use programs (BMY).
KOL is not sure INT-747 is the NASH compound of the future, and it looks stronger in primary biliary cirrhosis (PBC) (ICPT).
Positive on preclinical data from GenFit for GFT-505 in NASH but hasn’t seen enough data from Galectin (GALT).

For the full report, please download the PDF version at the top of this page.

For our disclosures, please read the BioMedTracker Research Standards. BioMedTracker will be offering KOL Reports and Physician Pulse Surveys through 2014 for purchase a la carte, or access to all reports and surveys can be purchased as a subscription to KOL Insight. For more information on KOL Insight subscription, please email BioMedTracker or call BioMedTracker Client Services at (858) 200-2357.

Indications Covered:

Hepatic Fibrosis
Hepatitis B (HBV) Treatment (Antiviral)
Hepatitis B Prevention (Vaccines, Antiviral)
Hepatitis C (HCV) (Antiviral)
Hepatitis C Prevention (Vaccines, Antiviral)
Non-Alcoholic Steatohepatitis (NASH)

Additional Resources: